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In most studies on hospital merger effects, the unit of observation is the merged
hospital, whereas the observed price is the weighted average across hospital
products and across payers. However, little is known about whether price
effects vary between hospital locations, products, and payers. We expand
existing bargaining models to allow for heterogeneous price effects and use a
difference‐in‐differences model in which price changes at the merging hospitals
are compared with price changes at comparison hospitals. We find evidence of
heterogeneous price effects across health insurers, hospital products and hospi-
tal locations. These findings have implications for ex ante merger scrutiny.
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An increasing number of empirical studies have been conducted concerning the price effects of hospital mergers. In
general, the aim of these studies is to test the effectiveness of antitrust policy. In competitive markets, the aim of
preventive merger control is to prohibit anticompetitive consolidation. To determine whether a merger between two
or more firms will result in anticompetitive price increases and/or quality decreases, antitrust authorities need to carry
out a prospective review of the merger. However, merger reviews in the health‐care sector encounter specific difficulties
because there are unique factors that render the most commonly used tests for measuring geographic markets less
reliable in health care than in other sectors (Elzinga & Swisher, 2011). Retrospective studies are aimed at providing a
better understanding of the effects of mergers, which, in turn, may improve future antitrust policy.
The majority of the studies on retrospective merger analyses indicate a positive correlation between hospital mergers
and prices (e.g., Gaynor & Town, 2012; Vogt & Town, 2006; Gaynor & Vogt, 2000 for reviews). In most of these studies,
the unit of observation is the merged hospital, whereas the observed price is the weighted average across different
hospital products and across different payers. However, little is known about whether price effects vary between differ-
ent hospital locations, different products, and different payers. Because merged hospitals often continue to operate at
different locations, produce multiple products, and negotiate prices with a range of payers, an interesting question is- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 ROOS ET AL.whether these differences matter. If it turns out that they do matter, this may have important implications for ex ante
merger scrutiny by antitrust authorities.
This article considers the question of whether the price effects of a hospital merger vary between locations, products,
and third‐party payers. By means of a hospital–insurer bargaining model, we show that the price effects of a hospital
merger may vary and that the differences between locations, products, and insurers may influence the outcome of
hospital–insurer price setting differently. We show that the price effects differ between locations, products, and insurers
depending on (a) the degree of substitution between the merging hospitals for different products, (b) the relative
bargaining ability of hospitals and insurers, and (c) the premerger price–cost margins. We then use a unique national
dataset on hospital–insurer negotiated contract prices for each hospital product in the Netherlands to investigate
whether the price effects of a merger between a general acute care hospital (henceforth hospital M1) and a neighboring
general acute care hospital that also provides tertiary hospital care (henceforth hospital M2) vary between different
hospital locations, different products, and different insurers.
In the remainder, we outline our theoretical model (Section 2) and explain its applicability to the Dutch context and
the merger considered (Sections 3–4). After this, we turn to our empirical analysis (Sections 5–7), concluding with a
summary of the main findings (Section 8).2 | THE MODEL
To explain the possibility of heterogeneous price effects of hospital mergers, we consider a game‐theoretical model of
hospital–insurer bargaining, following the lines suggested by Gaynor and Town (2012; hereafter: GT) and
Gowrisankaran, Nevo, and Town (2015; hereafter: GNT). These papers build on earlier literature analyzing hospital–
insurer bargaining, notably Gal‐Or (1997), Town and Vistnes (2001), Capps, Dranove, and Satterthwaite (2003), and
Gaynor and Vogt (2003).
To keep our model as simple as possible, we adopt a two‐stage setup following the base model of GNT. In the first
stage of this model, health insurers bargain and contract with hospitals on behalf of their insured, and in the second
stage, each consumer receives a health draw and seeks treatment at the hospital that maximizes his utility. Because
the consumer commits to a restricted network of hospitals when he buys health insurance, he has the option of visiting
any of the contracted hospitals when he is in need of specific care.
To be able to explain heterogeneous price effects over products, we need to allow for flexibility in the price ratios
between different products of the same hospital. Both the GT and the GNT models fix all product–price ratios at the
level of the respective disease–weight ratios. In their models, hospitals are constrained to negotiate a single base price
per hospital location and the prices for different products are computed as a product of the base price and the disease
weight.1 Our model (outlined in online appendix S1) deviates from this assumption by freeing the product–price
ratios. It thus allows for the situation in which a hospital may be contracted only for a subset of treatments. This
better matches practice where contracts between hospitals and insurers can be concluded for a subset of treatments
and a price has to be determined for each care bundle (e.g., Chernew, Mechanic, Landon, & Gelb Safran, 2011;
Delbanco, 2014; Song et al., 2014). In the United States, for example, we observe cases in which hospitals shifted
resources and activities to central profitable services while reducing or eliminating some loss making services (i.e., the
so‐called specialty service lines; Berenson, Bodenheimer, & Pham, 2006). This is in line with the anticipated strategy
change towards integrated care delivery systems (Porter, 2009) and further specialization of the health‐care market
because of quality considerations (Baicker & Levy, 2013; Ho, Town, & Heslin, 2007). Also in the Netherlands, which data
we use when estimating the model parameters, hospitals may be contracted only for a subset of services. Interviews with
health insurers and hospital representatives who were involved in contractual negotiations during our study period indi-
cated that especially for high‐revenue products insurers and hospitals bargain separate prices. In the Netherlands, it is
usually the insurers that initiate selective contracting of procedures. For example, one insurer selectively contracts pro-
viders of breast cancer surgeries (CZ, 2015), whereas another selectively contracts 15 hospital products (VGZ, 2014). As a
result of selective contracting or hospitals' choices, in practice, the full hospital or a subset of procedures in a hospital
may be contracted.1The disease–weights measure the mean resource usage by diagnosis. In the model, they reflect the resource intensity of treatment. Using the disease‐
weights with a base price does not allow for heterogeneous price effects of mergers.
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Following GT and GNT, we analyze hospital–insurer bargaining in a model with multiple hospitals and health insurers.
On the basis of the theoretical model outlined in online appendix S1, we obtain the following expression for price
change due to merger:
p jþkð Þmjd − pmjd ¼ bm sð Þ pmkd −mcmkdð Þdjkmd; (1)
where pmjd and p
jþkð Þ
mjd denote the prices that insurer m pays to hospital j for product d before and after merger, bm(s) is the
bargaining weight of health insurer m, pmkd denotes the prices that insurer m pays to hospital k for product d, mcmkd is
the marginal cost of providing product d in hospital k for health insurerm, and djkmd defines the disease‐specific diversion
share of patients of insurer m with illness d from hospital j to hospital k. A higher value of the diversion share suggests a
higher degree of substitution between two hospitals in treating this illness.
There are a few important conclusions that can be drawn from Equation (1) with respect to the price effect of a hos-
pital merger. The first important finding is that product d's price change after the merger in each hospital is increasing
in the diversion share between these hospitals. This result tells us that a merger will increase the product's price more if
the hospitals that partner in the merger are close substitutes with respect to that product. Therefore, if substitution
between hospitals is stronger for one product than for another product,2 the price increase after the merger will be
higher for the first product and hence hospital mergers may lead to heterogeneous price effects across different products
and different locations.
The second most important conclusion that follows from our model is that, according to Equation (1), the price
change caused by merger is proportional to the difference between the price and the marginal cost of the other hospital.
Merging with a hospital whose price of product d is higher, whereas the marginal cost are lower, would result in a
greater price increase (cp).
Finally, we observe, perhaps at first sight somewhat contra‐intuitively, that a price increase caused by merger is pro-
portional to the bargaining ability bm(s) of the insurer. This result suggests that, although a greater relative bargaining
ability of the insurer in comparison with hospitals provides the insurer with more leverage against these hospitals, this
leverage advantage is reduced after the merger of the hospitals.3 | THE DUTCH HOSPITAL MARKET
In this article, we estimate the price changes of a merger between two Dutch hospitals, and we use the theoretical result
from Section 2 (and online appendix S1) to interpret our empirical findings. The current Dutch health‐care system bears
important similarities with the model set up: Consumers buy health insurance from health insurers and health insurers
bargain and contract with hospitals on behalf of those that they insure. An insurer can also contract a hospital for a
subset of products.
In recent decades, the Netherlands, like several other OECD countries, has embraced a market‐oriented approach to
healthcare. After decades of strict governmental supply‐side regulation, the Dutch health‐care system is undergoing a
transition towards regulated competition (Schut & van de Ven, 2005).
Of particular importance are the introduction of the Health Insurance Act in 2006 and the introduction of hospital–
insurer bargaining in 2005. Under the Health Insurance Act, all Dutch citizens are obliged to buy standardized
individual basic health insurance from a private insurer. Having bought an insurance policy, the enrollee gets access
to all hospitals of the contracted network without co‐payments. As described in online appendix S1, there is an annual
deductible per adult individual, although most hospital product prices are higher than the fixed amount that is set by
the deductible3 and hence the deductible does not play a role in patients' hospital choices. The insurers' market shares
are relatively stable.2The substitution rates may differ across products, for example, because for some hospital products patients' willingness to travel might be higher,
there is more intense competition with nearby hospitals over those products or the transparency of different product markets differs.
3Just 11% of all patients received treatments that cost less than 165 euro in 2011. The prices of the products that we consider in our article all exceed
the deductible during the study period.
4 ROOS ET AL.Since 2005, the scope for free negotiations of prices between hospitals and health insurance companies has gradually
increased from 10% of hospital revenue in 2005, to 20% in 2008, to 34% in 2009, and to 70% in 2012. For the remaining
part, hospital prices are still regulated. For products and services included in the free‐pricing segment, each hospital
typically renegotiates the terms of its contracts with health insurers on an annual basis. Over the years, the number
of health insurers offering contracts with restricted provider networks or policies that only cover a subset of treatments
in hospitals has increased.4 | THE MERGER
Dutch local and regional hospital markets are highly concentrated.4 Between 2005 and 2012, 17 mergers involving 34
hospitals were cleared by the Dutch competition authority (Authority for Consumers and Markets [ACM]). All mergers
took place between neighboring hospitals.
The merger that we study was consummated in year t (which was between 2005 and 2012).5 The merger was notified
to the ACM prior to taking place.6 Following the notification, the ACM carried out a general review of the proposed
merger in which they made inferences regarding the expected anticompetitive effects of the merger on the market.
The merger was cleared after the first general review. The decision to clear the merger evoked criticism by health econ-
omists, however, who argued that the prospective merger analysis by the antitrust authority had been lacking and that it
was likely that the merger had created a dominant position for the two hospitals involved (Varkevisser & Schut, 2008).
Hence, this merger seems to be on the enforcement margin, making it an interesting case for further retrospective
studies.4.1 | The locations
The merger involved a general acute care hospital (hospital M1) and a neighboring general acute care hospital that also
provides tertiary hospital care (hospital M2). Hospital M1 is located in an isolated geographical area, whereas hospital
M2 is located in a more densely populated region with several other hospitals nearby. The distance between hospitals
M1 and M2 is about 50 km. According to the ACM, the merging hospitals were subject to competition from five other
hospitals before the merger took place. Prior to the merger, hospital M2 was the largest competitor to hospital M1,
whereas hospital M2 had multiple competitors. After the merger, hospital M1 was expected to experience competitive
pressure from only one rival hospital, whereas hospital M2 was expected to experience notable competitive pressure
from five other hospitals.7 The differences in competitive pressure in the markets of hospitals M1 and M2 may result
in heterogeneous price effects of the merger (see Section 2).4.2 | The products
In this article, we estimate the impact of the merger in three separate product markets that jointly make up 47.5% of the
merged hospital's turnover in the segment for which Dutch insurers and hospitals were allowed to freely negotiate
prices at the time of the merger. We looked at hip replacements, knee replacements, and cataract surgery. Most hospi-
tals provide these services. At time of the merger, there were no independent treatment centers (ITCs) in the regional4In 2006, the average HHI of Dutch hospitals equaled 2.350 (Halbersma et al., 2010), and since then, no hospitals entered or exited the hospital market.
Only mergers have decreased the number of hospitals.
5For reasons of confidentiality, we only report those results that are of direct interest to this article. We anonymize the names of the merged hospitals,
rival hospitals, and insurers. For the same reason, the merger year is reported as t (which was between 2005 and 2012), with the year preceding the
merger as t − 1 and the year following the merger as t + 1.
6According to most antitrust laws, mergers must be reported to an antitrust authority prior to consummation (see 15 USC §18A for the US and the
competition laws of the EU Member States or EC (European Commission), 2004 for the European Union's rules on prior merger notification). The
Dutch antitrust law is no exception (Mededingingswet, section 37.2).
7None of these rivals provides tertiary hospital care.
TABLE 1 Descriptive statistics
Hospitals
Hip replacements Knee replacements Cataract surgery
t − 1 t + 1 t − 1 t + 1 t − 1 t + 1
Panel A. Hospital M1
Volume 174 175 223 293 387 361
Gender (% male) 0.28 0.38 0.34 0.43 0.38 0.35
Patients' average age 68 68 64 56 72 73
Patients' average SES score 0.05 −0.14 0.15 0 0.09 −0.06
Panel B. Hospital M2
Volume 390 511 271 299 2144 2113
Gender (% male) 0.34 0.35 0.34 0.32 0.41 0.40
Patients' average age 68 70 69 69 72 73
Patients' average SES score 0.31 0.42 0.39 0.48 0.35 0.42
Panel C. Rival 1
Volume 165 154 164 135 1026 1045
Gender (% male) 0.27 0.36 0.27 0.29 0.41 0.37
Patients' average age 70 71 71 69 75 75
Patients' average SES score −0.22 −0.05 −0.06 −0.09 −0.09 −0.02
Panel D. Rival 2
Volume 237 195 162 162 881 1088
Gender (% male) 0.32 0.34 0.32 0.38 0.43 0.41
Patients' average age 70 68 68 68 73 72
Patients' average SES score 0.15 0.12 0.15 0.28 0.22 0.26
Panel E. Rival 3
Volume 136 114 146 118 650 972
Gender (% male) 0.34 0.28 0.40 0.29 0.38 0.42
Patients' average age 70 62 70 70 75 74
Patients' average SES score −0.83 −0.88 −0.76 −0.69 −1.01 −0.96
Panel F. Rival 4
Volume 169 155 101 151 855 763
Gender (% male) 0.34 0.26 0.38 0.35 0.43 0.44
Patients' average age 69 73 70 71 75 75
Patients' average SES score 0.24 0.46 0.09 0.36 0.17 0.4
Panel G. Other hospitals
Average volume 231 (14) 234 (15) 196 (12) 199 (12) 1590 (146) 1545 (137)
Gender (% male) 0.33 0.34 0.32 0.33 0.39 0.41
Patients' average age 69 (0.37) 69 (0.25) 69 (0.27) 69 (0.26) 73 (0.32) 73 (0.29)
Patients' average SES score −0.04 (0.05) −0.18 (0.08) 0 (0.05) −0.11 (0.07) 0.01 (0.05) −0.09 (0.07)
Note. The standard deviations are in parentheses. We excluded all hospitals that had more than 15% missing prices for either hip or knee replacements or cat-
aract surgeries in the period t − 2 to t + 2. Panel G displays the descriptive statistics of the hospitals other than hospitals M1, M2, and the rival hospitals. Within
panel G, 51 hospitals performed hip replacements, 56 hospitals performed knee replacements, and 57 hospitals performed cataract surgeries. The rows on vol-
ume only report cases that have a valid gender, age, and SES score.
ROOS ET AL. 5market. Table 1 presents descriptive statistics on the patients for each product in hospitals M1 and M2 and four rivals8
before and after the merger.
After merger, the hospitals had an opportunity to concentrate care in one of the two hospital locations. This does not
seem to have occurred, however. Even though it follows from Table 1 that hospital M2 provided many more hip replace-
ments in year t + 1 than in t − 1, the total number of hip replacements in the market barely changed, and the provision
of hip replacements in hospital M1 also did not change significantly. The hospitals therefore do not seem to have con-
centrated care in hospital M2 after the merger. Rather, it seems that hospital M2 is, postmerger, better able to attract
patients in need of hip replacements because the number of hip replacements performed in rival hospitals decreased
slightly whereas the total number of patients in the market did not change significantly.
In hospital M1, the average age of patients undergoing knee replacements dropped between t − 1 and t + 1. Again,
this does not seem to be an attempt to change patient flows in the merged hospitals, as, according to hospital M1's8We excluded the fifth rival hospital from the analysis, because it had more than 15% missing prices in the period t − 2 to t + 2.
TABLE 2 Health insurers' market share per product per hospital in t − 1 and t + 1
Hospitals
Market Share
Insurer 1
Market Share
Insurer 2
Market Share
Insurer 3
Market Share
Insurer 4
Market Share
Insurer 5
t − 1 t + 1 t − 1 t + 1 t − 1 t + 1 t − 1 t + 1 t − 1 t + 1
Panel A. Hospital M1
Hip replacements 0.76 0.74 0.05 0.04 0.09 0.13 0.05 0.02 0.05 0.07
Knee replacements 0.69 0.61 0.05 0.06 0.16 0.20 0.06 0.08 0.05 0.06
Cataract surgery 0.84 0.77 0.01 0.03 0.09 0.09 0.04 0.05 0.02 0.06
Panel B. Hospital M2
Hip replacements 0.62 0.62 0.08 0.06 0.19 0.17 0.04 0.06 0.07 0.08
Knee replacements 0.69 0.62 0.04 0.03 0.17 0.20 0.01 0.06 0.09 0.08
Cataract surgery 0.70 0.71 0.04 0.05 0.16 0.14 0.02 0.03 0.08 0.08
Note. The health insurers' market shares are based on the number of cases per hospital–insurer–product combination.
6 ROOS ET AL.website, the hospital has been testing out an innovative procedure for knee replacements since year t for which only
patients under 60 years old are eligible. This is likely unrelated to the merger but could explain the decrease in the
patients' average age observed in the data.4.3 | The health insurers
At the time of the merger, at least five health insurers were active in the region.9 According to Table 1, the volume of
patients has not changed significantly across hospitals, indicating that health insurers did not shift enrollees away from
the merged hospitals to rival hospitals in t + 1.
Table 2 shows the insurers' market share for each product and for each hospital in years t − 1 and t + 1. The market
shares have not changed over the years.5 | EMPIRICAL MODEL SPECIFICATION
We use data on hospital–insurer negotiated contract prices in the Netherlands for each of the three hospital products
considered, to investigate whether the merger between hospitals M1 and M2 has led to price changes and if so, whether
this effect varies between locations, payers, and products.
Because we wanted to control for price changes that would have occurred even if the merger had not taken place,
we used a difference‐in‐differences (DID) model in which price changes at the merging hospitals are compared with
price changes among a group of comparison hospitals that were unaffected by the merger (i.e., the control group).
The identifying assumption of a DID estimation is that trends (price trends) would be the same in both groups in
the absence of the event (merger). We visually investigated whether the common trend assumption applies
(Figures 1–3). Although we only have 2 years of premerger data, the graphs suggest that the premerger price change
in the merged hospital did not deviate substantially from the premerger price changes in Control Group 1.
To examine the effect of aggregating the merger price effect, we estimated DIDs models at various aggregation levels.
As a benchmark, we started with the most aggregated model, which is the price effect for the merged hospital fully aggre-
gated over hospital locations, products, and insurers. We then disaggregated this effect stepwise to ultimately arrive at the
most differentiated model in which we fully differentiated the merger price effect across hospital locations, products, and
insurers.
The most aggregated model:
lnpjt ¼ αþ λ·POSTt þ δ·POSTt·MERGEDj þ ϑj þ εjt; (2)9In fact, there are six health insurers active in the region. However, for the sixth health insurer, we did not have valid prices in the post‐merger year
(t + 1) for the merging hospitals M1 and M2. This health insurer was therefore not included in the DIDs estimates or in any other analysis. The effect
of excluding this health insurer for hospital M1 and hospital M2 is most likely negligible, however, because the health insurer only accounts for less
than 2% of all hip, knee, and cataract patients in hospitals M1 and M2.
FIGURE 1 Average price development
hip replacements in Hospitals M1, M2,
and Control Group 1. Notes. The prices
plotted for Control Group 1 are averaged
over all hospitals in Control Group 1
FIGURE 2 Average price development
knee replacements in Hospitals M1, M2,
and Control Group 1. Notes. The prices
plotted for Control Group 1 are averaged
over all hospitals in Control Group 1
FIGURE 3 Average price development
cataract surgery in Hospitals M1, M2, and
Control Group 1. Notes. The prices plotted
for Control Group 1 are averaged over all
hospitals in Control Group 1
ROOS ET AL. 7where pjt was the weighted average hospital negotiated price,
10 POSTt is one in year t + 1 (the postmerger year) and zero
in year t − 1 (the premerger year), MERGEDj is one for the merger hospitals and zero for the control group hospitals,
λ · POSTt denotes the change in the average price in year t + 1 compared with year t − 1, δ is the DID estimator (i.e., the10First, for the results presented in this paper we calculated an average price per product for each hospital–insurer pair. Second, we aggregated these
prices over the insurers to an average price for each hospital‐product combination, whereby we weighted the prices with the insurer's specific volume
shares in year t − 1. Third, we aggregated over the products to an average price per hospital, whereby we weighted the hospital‐product prices with the
market‐wide revenue shares for each product in t − 1. We calculated an average price for the merged entity M1 + M2, by weighting the prices for
hospitals M1 and M2 with their corresponding revenue shares in year t − 1. In online appendix S2 we present the models using the per hospital‐
product revenue in t − 1 as a weighting factor for the aggregation over products (second step).
8 ROOS ET AL.average treatment effect on the treated) and ϑj is a hospital fixed effect. To account for potential endogeneity of the
merging policy, we matched a control group to the event group (i.e., hospitals M1 and M2). In this control group, we
included all Dutch hospitals that provided the three products and excluded any other hospitals that also merged
between years t − 2 and t + 2 and ITCs.
To estimate the most aggregated DID model, we aggregated the patient‐level hospital data to an average price per
hospital. In the Netherlands, negotiated prices differ between health insurers but not between patients with the same
health insurer who are treated in the same hospital. Therefore, we can aggregate the data to hospital–insurer level with-
out a loss of information. Furthermore, due to aggregation, we do not have to consider the correlation between prices
within each hospital–insurer combination, which would otherwise lead to biased standard errors (see, e.g., Bertrand,
Duflo, & Mullainathan, 2004; Donald & Lang, 2007; Thompson, 2011). We investigated whether our results from
the disaggregated model were robust to changes in the control groups by using six different control groups11: (a) all
Dutch hospitals that provide the product, excluding hospitals that also merged between years t − 2 and t + 2 and ITCs;
(b) Control Group 1, excluding all university hospitals; (c) Control Group 2, excluding rivals of the merged hospitals;
(d) Control Group 3, excluding the hospitals with low market power; (e) Control Group 3, excluding all hospitals with
low health insurers concentration; and (f) Control Group 3, excluding hospitals of a different size to hospitals M1 and
M2. We thus had 12 control groups, six for each hospital. Finally, we also tested whether our disaggregated model was
robust to hospital‐specific covariates.126 | DATA
We used a comprehensive nationwide patient‐level dataset containing all inpatient and outpatient visits at all hospitals
in the Netherlands. For each visit, the patient's zip code, age (year of birth), gender, health insurer, and DTC were
observed, as well as the price negotiated for each hospital–insurer–product combination between years t − 2 and
t + 2. For the DID analysis, we use data from t − 1 to t + 1. The patient‐level data that we used came from the insurers'
claims administration and hospital registries.
We focused on three products for which prices are freely negotiable: hip replacements,13 knee replacements14 (both
orthopedics), and cataract surgery15 (ophthalmology). In year t − 1, these product markets jointly accounted for 47.5% of
turnover in the free‐pricing segment at the merging hospitals. All hospitals where more than 15% of prices were missing
for 1 or more years between t − 2 and t + 2 were excluded from the dataset.16
The premerger price was based on data from the year preceding the merger (t − 1), and the postmerger price was
based on data from the year after the merger (t + 1). Table 3 presents summary statistics on the volume and mean prices
of the products within hospital M1, hospital M2, and Control Group 1.
Hospitals with limited market power are excluded from Control Group 4. The weighted average market share that
was used to determine the hospitals' market power was based on the LOgit Competition Index (LOCI), developed by
Akosa Antwi, Gaynor, and Vogt (2006, 2009). According to this model, the market share of hospital j for product d
in zip code z is sjd;z ¼
qjd;z
∑Jj¼1qjd;z
, where qjd,z is the total number of patients at hospital j (j = 1,..,J) for product d11The results presented in the main text relate to Control Group 1. The results for all six control groups are reported in online appendix S7.
12The following hospital‐specific covariates were included in an additional DID model: the number of patients, the percentage of males, the average
socioeconomic status score, the average age of the patients, and the weighted market share per hospital. The results using this model did not differ
from the results by the other models. These are therefore not included in the main text but reported in online appendix S3.
13According to the Dutch hospital product classification system: “joint degeneration of pelvic/hip/upper leg; surgery with clinical admission and joint
prosthesis.”
14According to the Dutch hospital product classification system: “joint degeneration of knee; surgery with clinical admission and joint prosthesis.”
15According to the Dutch hospital product classification system: “cataract; outpatient treatment with intervention.”
16For hip replacements, 31 out of 90 hospitals had more than 15% missing prices in one or more years in the period t − 2 and t + 2. For knee replace-
ments, 25 out of 89 hospitals had more than 15% missing prices in one or more years in the period t − 2 to t + 2. For cataract operations, 25 out of 89
hospitals had more than 15% missing prices in one or more years in the period t − 2 to t + 2. The threshold of 15% was arbitrary. As a sensitivity check,
we therefore also used other thresholds for the disaggregated model. This had no effect on the overall results or the conclusions of the article. The
results are available in online appendix S4.
TABLE 3 Volume and mean prices for hip and knee replacements and cataract surgery in hospitals M1, M2, and Control Group 1
Hospitals
Hip replacements Knee replacements Cataract surgeries
t − 1 t + 1 t − 1 t + 1 t − 1 t + 1
Panel A. Hospital M1
Volume 172 173 222 282 381 355
Mean price in € 9,189.58 (348.00) 10,188.05 (559.08) 11,022.98 (494.94) 11,291.41 (651.32) 1,405.00 (40.78) 1,421.27 (45.08)
Panel B. Hospital M2
Volume 389 503 271 295 2,140 2,077
Mean price in € 9,181.96 (144.25) 8,991.34 (109.09) 10,959.49 (185.30) 10,321.76 (245.90) 1,400.10 (20.34) 1,313.40 (29.83)
Panel C. Control
Group 1
Volume 224 227 189 194 1,520 1,498
Mean price in € 9,045.00 (338.64) 9,160.96 (620.08) 10,592.34 (473.51) 10,608.52 (786.32) 1,340.94 (72.83) 1,349.43 (104.12)
Notes. The hospitals' volume per product in this table slightly deviates from the hospitals' volume per product reported in Table 1. In this table, we only report
the records with a valid price, whereas in Table 1 only records with a valid gender, age, and SES score per product per hospital are reported. The mean prices for
each hospital are averaged over all patients. The mean price for Control Group 1 is the average over the mean prices of the hospitals within control group 1. The
standard errors are in parentheses.
ROOS ET AL. 9(d = 1,2,3) in zip code z (z = 1,...,Z). Then, for each hospital and product, we calculated a weighted average market share
sjd ¼ ∑Zz¼1wjd;zsjd;z, where we weighted each market share with the share of patients coming to hospital j from zip code
z, that is, wjd,z=
qjd;z
∑Zz¼1qjd;z
.
The insurer's HHI that was used to construct Control Group 5 is based on the insurer's market shares for each prod-
uct and ranged from zero to one. The insurer's HHI for hospital j and product d: insurer's HHIjd = ∑
M
m¼1
qmjd
∑Mm¼1qmjd
 2
,
where qmjd is the total number of patients of insurer m (m = 1, …,M) in hospital j for product d.7 | EMPIRICAL RESULTS
As expected, the weighted average market shares of the hospitals' products increased as a result of the merger. The
increase is from 76.7% to 82.5% for hip replacements, from 78.2% to 85.7% for knee replacements, and from 83.5% to
86.6% for cataract surgeries. In Table 4, we present the diversion shares of hospitals M1 and M2 that follow from the
bargaining model presented in Section 2 and online appendix S1. A higher value of the diversion share suggests a higher
degree of substitution between two hospitals in treating the same disease.17
From Table 4, it follows that the diversion shares of hospital M1 to hospital M2 are much higher. Hospital M1 is
located in a more isolated region with hospital M2 being its strongest competitor premerger. As expected, a large share
of patients is diverted to hospital M2 once hospital M1 is not available. If the more centrally located hospital M2 would
not be available, however, only few patients are expected to be diverted to hospital M1. When comparing the diversion
shares over products, we find that the variation in diversion shares across products within each hospital is much smaller
than the variation in diversion shares across hospital M1 and M2 for each product.
Table 5 presents the results of the DID model aggregated over locations, insurers, and products.
Table 5 shows that no significant merger effect was observed when the result was aggregated over locations, insurers,
and products.
In Table 6, we disaggregate the merger effect by location, product, and insurer.18
We disaggregated the postmerger price change for each hospital location to see whether the merging hospital differ-
entiated a potential price increase after merger across locations. When we used the DID approach, we found that the
postmerger increase in prices for hip replacements in hospital M1 varied significantly from the control group, whereas
the prices for hip replacements in hospital M2 were unaffected by the merger. Apparently, the merged hospital differ-
entiated its prices across locations.17Diversion ratios and market shares of rivals are reported in online appendix S5.
18The results of the stepwise disaggregation are presented in online appendix S6.
TABLE 5 Merger effect aggregated over all three products, health insurers, and hospital locationsa
Coefficients Hospitals M1 and M2
(Intercept) 8.869*** (0.029)
Postmerger price change in the common trend (λ) 0.009 (0.009)
Postmerger price change −0.017 (0.057)
Observations (number of hospitals) 54
R2 0.719
Adjusted R2 0.422
Notes. Models estimated by ordinary least squares with standard errors in parentheses. In this model, hospitals M1 and M2 together are compared with Control
Group 1.
aFor clarity reasons, we do not report the hospital dummies here.
***Significant at the 1 percent level. **Significant at the 5 percent level. *Significant at the 10 percent level.
TABLE 4 Diversion shares to/from hospitals M1 and M2 (in t − 1)
Hip replacements Knee replacements Cataract surgery
To\from M1 M2 M1 M2 M1 M2
M1 — 0.105 — 0.158 — 0.034
M2 0.735 — 0.663 — 0.850 —
Notes. The diversion shares are calculated using a conditional logit model of hospital choice, following Capps et al. (2003). We used patient‐level data from t − 1
to estimate the model, which included the travel time between the patient's zip code and hospital location, a dummy indicating whether the patient is older or
younger than 65 years old, a dummy for the patient's gender, and the socioeconomic status score for the patient's zip code.
TABLE 6 Merger effect for hip and knee replacements and cataract surgery per health insurer in hospitals M1 and M2a
Coefficients Hip replacements Knee replacements Cataract surgeries
Panel A. Hospital M1
(Intercept) 9.130*** (0.026) 9.311*** (0.031) 7.249*** (0.028)
Postmerger price change in the common trend (λ) 0.014* (0.007) 0.004 (0.008) −0.015** (0.007)
Postmerger price change insurer 1 0.113** (0.053) 0.049 (0.062) 0.037 (0.057)
Postmerger price change insurer 2 0.099* (0.053) 0.024 (0.062) −0.053 (0.057)
Postmerger price change insurer 3 −0.118** (0.053) −0.153** (0.062) −0.114** (0.057)
Postmerger price change insurer 4 0.157*** (0.053) 0.089 (0.062) 0.067 (0.057)
Postmerger price change insurer 5 0.147*** (0.053) 0.080 (0.062) 0.059 (0.057)
Observations (number of hospitals) 57 62 63
R2 0.828 0.767 0.740
Adjusted R2 0.617 0.487 0.429
Panel B. Hospital M2
(Intercept) 9.130*** (0.026) 9.311*** (0.031) 7.249*** (0.028)
Postmerger price change in the common trend (λ) 0.014* (0.007) 0.004 (0.008) −0.015** (0.007)
Postmerger price change insurer 1 −0.032 (0.053) −0.066 (0.062) −0.051 (0.057)
Postmerger price change insurer 2 −0.029 (0.053) −0.035 (0.062) −0.016 (0.057)
Postmerger price change insurer 3 −0.049 (0.053) −0.084 (0.062) −0.074 (0.057)
Postmerger price change insurer 4 −0.021 (0.053) −0.016 (0.062) −0.010 (0.057)
Postmerger price change insurer 5 −0.044 (0.053) −0.049 (0.062) −0.022 (0.057)
Observations (number of hospitals) 57 62 63
R2 0.738 0.716 0.706
Adjusted R2 0.417 0.375 0.354
Notes. Models estimated by ordinary least squares with standard errors in parentheses. In this model, hospitals M1 and M2 are compared with Control Group 1.
aFor clarity reasons, we do not report the hospital dummies here.
***Significant at the 1 percent level. **Significant at the 5 percent level. *Significant at the 10 percent level.
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significantly between hospital products. Specifically, the merger resulted in higher prices for hip replacements in hos-
pital M1, whereas the prices for knee replacements and cataract care in hospitals M1 and M2 remained unaffected.
Finally, we disaggregated the postmerger price changes for each hospital–insurer combination. For four out of five
health insurers that negotiated prices with hospital M1, the postmerger price increases for hip replacements were on
average 13 percentage points higher than for the control groups. The merger's price effect varied between health
insurers from −12 to +16 percentage points relative to the control groups. Also, the largest health insurer—Insurer
1, which represented 76% of hospital M1's patients—was unable to negotiate lower prices: The prices it paid for hip
replacements rose by 11 percentage points as a result of the merger. In contrast, one of the four other much smaller
health insurers—Insurer 3, which represented only 11% of hospital M1's patients—was able to negotiate prices that
were much lower than the control groups. These results were robust between the control groups. It is therefore less
likely that the merger effect estimated was driven by unobserved characteristics in the control group.198 | DISCUSSION
The main finding of our study is that a merger between two hospitals in overlapping geographical markets generated
heterogeneous prices effects at the two different hospital locations, for different hospital products, and for different
health insurers. The theoretical model that was presented in Section 2 and online appendix S1 explains why this might
be the case.8.1 | Different price effects for different products
First, we find a significant increase in the postmerger price of hip replacements but not of the other two products. This
result was robust across all control groups and model specifications.
This raises the question of why the price rise only occurred for hip replacements and not for knee replacements and
cataract surgery. It followed from the theoretical framework that product d's price change after the merger in each hos-
pital is increasing in the diversion share between these hospitals and the price–cost margin of the partnering hospital.
We found that the diversion shares in hospital M1 of hip replacements were no higher than the diversion shares of other
products. Hence, the difference in product–price effects after merger must be explained by other factors, that is, the pre-
merger price–cost margins of hospital M2. Unfortunately, we have no information on the product's price–cost margins
of hospitals in this market. However, because the premerger prices for hip replacements in hospitals M1 and M2 were
remarkably similar according to Table 3, the theory suggests that the premerger cost of hip replacements at hospital M2
were lower than the premerger cost of hip replacements at hospital M1.
Nevertheless, the finding that price effects are heterogeneous across hospitals' top‐revenue products highlights the
importance of using a more disaggregated approach rather than the more aggregated approach, when defining product
markets. In practice, finding alternatives to highly debated traditional approaches to delineate geographic markets in
health care have been the top priority of most antitrust authorities. With the emergence of promising alternatives, like
merger simulation models, ex ante merger scrutiny could further improve by a better delineation of product markets. In
antitrust cases, it is often assumed that the merger price effect will be the same for all hospital products because acute
care, inpatient services can be considered as a single and thus homogeneous hospital product in cases of hospital
mergers. According to antitrust laws, however, separate products or services need to be distinguished if they are not
demand or supply substitutes.20 Because the hospital market is highly complex due to the multiplicity of services offered
and the heterogeneity of consumers, many different hospital products exist and the standard inpatient cluster may mask
considerable variability in the concentration statistics across the inpatient categories that make up an overall cluster.
Sacher and Silvia (1998) therefore argue that disaggregation can provide a better understanding of the potential19These findings are reported in online appendix S7.
20According to the European Commission (1997) Commission Notice, “A relevant product market comprises all those products and/or services which
are regarded as interchangeable or substitutable by the consumer, by reason of the products’ characteristics, their prices and their intended use.”
According to the Federal Trade Commission (2010) Merger Guidelines: “Market definition focuses solely on demand substitution factors, i.e. on con-
sumers' ability and willingness to substitute away from one product to another in response to a price increase or a corresponding non‐price change
such as a reduction in product quality or service.”
12 ROOS ET AL.competition effects of a merger in a range of market configurations and that more attention to better product delinea-
tion in hospital markets is warranted. A similar point is made by Hentschker, Mennicken, and Schmid (2014).
Also from the theoretical model it followed that price effects after merger may differ between hospital products. As
indicated in Section 2, freeing the product price ratios would more closely correspond to practices where contracts
between hospitals and insurers can be concluded for a subset of treatments and a price has to be determined for each
care bundle. For that reason, when we estimated the model parameters, we also disaggregated the effects of the merger
by product markets. However, if the rules for product market definition were applied strictly, hundreds or maybe thou-
sands of separate hospital product markets would have to be distinguished because many hospital products and services
are not demand or supply substitutes. Clearly, this would not be a feasible strategy in cases of hospital mergers. Hence,
only a certain level of disaggregation would be warranted. Although our theoretical model defines each product d as a
treatment of one illness, d may also be understood as a product cluster combining several illnesses based on revenue or
volume or specialism or otherwise. Hence, the model conclusions also hold for the situation in which some clustering
(aggregation) is applied in order to reduce the number of product dimensions in the analysis or because this more
closely corresponds with selective contracting in practice. Sacher and Silvia (1998) show that even a very limited disag-
gregation of the standard inpatient cluster can lead to a more accurate merger analysis. Zwanziger, Melnick, and Eyre
(1994), too, propose a manageable disaggregation of the standard clusters. So far, in practice, antitrust authorities have
only occasionally taken potential differences between products into account.21 Recently, however, the Dutch competi-
tion authority concluded that the increasing trends towards more specialization and the development of integrated care
networks necessitate a further and more formal disaggregated approach to define relevant hospital product markets. It
announced that hospitals and independent treatment centers that wish to merge will now need to provide the Dutch
competition authority with detailed information on the potential effect of the merger per patient group22 (ACM,
2018). Because it is unclear how often antitrust outcomes would be affected by using a different level of aggregation
(Sacher & Silvia, 1998), we suggest using both the clustered approach and a limited disaggregated approach when defin-
ing product markets in the case of hospital mergers. If the initial disaggregated approach yields different outcomes, the
analysis can be further disaggregated.
The question then remains how an antitrust authority should deal with differences in merger outcomes between
products. It is unlikely that the antitrust authority will block a merger if the prospective analysis indicates that the prices
for one product will increase, whereas the prices of other products will not be affected. Rather, finding different effects
across products may lead to interventions that are specifically addressed only to the product that is found to be affected
by the merger. For example, antitrust authorities may impose remedies requiring the divestiture of a specific product,
imposing the obligation to support new entrants (like ITCs) or introducing a price ceiling on particular products at
one or more hospital locations.8.2 | Different price effects at different locations
Second, the merged hospital raised its price for hip replacements significantly at one location (hospital M1) but not at
the other (hospital M2). To establish whether the merging hospitals experienced different price changes after merger, we
aggregated the postmerger price change according to hospital location. It followed from the theoretical model that price
changes caused by merger are proportional to the merging hospitals' diversion shares and the initial price–cost margins
of the merger partner. To date, however, most studies have not controlled for this potential source of heterogeneity.
Only Tenn (2011) examines and finds evidence of differential pricing strategies after merger.
In our case study, the merging hospitals' diversion shares were different due to their geographic location. The differ-
ences in geographic locations manifest itself in higher diversion shares for hospital M1 than for hospital M2 before
merger (Table 4). After the merger, the two hospitals were likely able to internalize this constraint, leading to higher
prices at hospital M1. Our results are consistent with this line of reasoning: The price change after merger was higher
for hospital M1 whose diversion shares to hospital M2 were much higher than the diversion shares from hospital M2 to
hospital M1.21For example, in one case the UK Competition Commission performed a detailed analysis of the appropriate product markets (Competition Commis-
sion, 2013) and in the FTC v. ProMedica Health System case, the U.S. antitrust authority paid special attention to the inpatient obstetrical services in
addition to general acute‐care inpatient services (Federal Trade Commission, 2012).
22There are 65 patient groups, which were developed by the Dutch Healthcare Authority. Each patient group is a cluster of patients having a similar
diagnosis.
ROOS ET AL. 13It needs to be recognized that a merger between a rather isolated hospital location and its closest substitute creates
opportunities for postmerger price increases that may be overlooked when not taking the disaggregated approach. Our
findings suggest that the competition intensity that merging locations experience before and after merger may differ
considerably between locations even if the merger entails two neighboring hospitals. Because this difference may result
in a heterogeneous merger effects across locations, antitrust agencies should take the difference between locations into
account. However, then the question remains how antitrust authorities should deal with differences in merger outcomes
between locations. We discussed product‐specific remedies in the previous paragraph. Likewise, antitrust authorities
may think about location‐specific remedies in case they predict the merger effect to be differentiated across locations.
Like product‐specific remedies, location‐specific remedies might entail structural remedies or behavioral remedies that
are only aimed at the location(s) that is (are) affected by merger.23
8.3 | Different price effects for different insurers
Third, we showed that the price change caused by merger may differ between health insurers. For four out of five health
insurers that negotiated prices with hospital M1, the postmerger price increases for hip replacements were on average
13 percentage points higher than the control group. The merger's price effect varied between health insurers from −12
to 16 percentage points relative to the control group. This finding corresponds to the results from an earlier retrospective
study from the United States (Thompson, 2011).
The theoretical model suggests that the insurer‐specific price differences may arise due to differences in the insurers'
bargaining abilities. In particular, a health insurer with more bargaining weight or ability is confronted with a higher
price increase after the merger. In our empirical analysis, we found some evidence for this somewhat counterintuitive
theoretical finding: that is, the postmerger price of hip replacements in hospital M1 negotiated by the largest health
insurer increased much more than the price negotiated by a much smaller insurer.
The source of bargaining ability of health insurers is the topic of many studies. The evidence suggests that idiosyn-
cratic effects such as bargaining skills of the individuals at the negotiating table might have a sizeable impact on the
market outcomes (Grennan, 2014; Halbersma, Mikkers, Motchenkova, & Seinen, 2010). Although the bargaining model
gives us some ideas on the source of heterogeneity in the postmerger price effects across health insurers, it remains
largely unclear why such large differences exist across insurers within markets and why some health insurers experi-
ence price increases whereas others experience price decreases after merger.
From a policy perspective, the fact that postmerger price effects are not homogeneous across insurers within markets
is an interesting finding, however. It is furthermore interesting to note that the heterogeneities are large. In ex ante
merger reviews in the Netherlands, the Authority for Consumers and Markets (ACM) asks representatives of large
health insurers in the region about their expectations regarding competitive effects of the merger. Like in most other
prospective merger cases, the largest health insurers in the relevant hospital market notified the competition authority
that they did not anticipate negative competitive effects from the consolidation that we studied. Partly because of that
reason the merger was cleared. However, the retrospective analysis indicates that the health insurers who believed to be
able to counteract postmerger price increases were both not able to do that. We therefore suggest that a more critical
assessment of health insurers' bargaining ability in merger cases is warranted.9 | CONCLUSION
In this study, we expanded existing bargaining models to allow for heterogeneous product–price effects and used a DID
model in which price changes at the merging hospitals are compared with price changes at a group of comparison hos-
pitals. The main finding of our study is twofold. First, the merger led to heterogeneous prices effects for different health
insurers, hospital products, and hospital locations. Second, these differences depend on (a) the degree of substitution
between hospitals, which may also vary over products, (b) the relative bargaining ability of hospitals and insurers,
and (c) the premerger price–cost margins of different products delivered by these hospitals.23Occasionally, antitrust authorities have opted for imposing remedies at the entire location level. Divestitures of hospital locations were, for example,
ordered by the U.S. antitrust authority in the FTC v. ProMedica Health System case (Federal Trade Commission, 2012) and by the German antitrust
authority in the Asklepios/LBK Hamburg case (Bundeskartellamt, 2005), whereas in the Evanston Northwestern/Highland Park Hospital case the U.
S. antitrust authority imposed a firewall so that the two merged hospital locations had to negotiate separately with insurers after merger (Federal Trade
Commission, 2008). See Gowrisankaran et al. (2015) for a critical review of the latter remedy.
14 ROOS ET AL.The theoretical model provided us with valuable insights on the sources of heterogeneity, whereas our detailed
empirical analysis of a hospital merger improved our understanding of the magnitude of differences. The analysis, how-
ever, also gives rise to three areas for future research. First, it would be interesting to replicate this study for different
hospital mergers to find out which of our findings persist. Second, more insight into the sources of insurers' bargaining
ability would be valuable. Third, analysis of premerger price–cost margins will improve our understanding of heteroge-
neous postmerger price effects across products.
Nevertheless, the fact that price effects of a merger are heterogeneous across products, locations and insurers signals
important conclusions for ex ante merger scrutiny. First, it highlights the importance of using a disaggregated approach
rather than the current cluster approach when defining relevant hospital product markets. Second, it suggests that
future prospective merger analyses should take potential differences across hospital locations into account. Finally, it
asks for a critical assessment of health insurers' bargaining ability in merger cases.ACKNOWLEDGEMENTS
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